A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
Latest Information Update: 07 Dec 2022
At a glance
- Drugs Venanprubart (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Dec 2022 Status changed from active, no longer recruiting to completed.
- 06 Jul 2022 Planned End Date changed from 16 Feb 2023 to 24 Feb 2023.
- 06 Jul 2022 Planned primary completion date changed from 16 Feb 2023 to 24 Feb 2023.